Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Net Income (2021 - 2025)

Prime Medicine's Net Income history spans 5 years, with the latest figure at -$47.5 million for Q4 2025.

  • For Q4 2025, Net Income fell 12.42% year-over-year to -$47.5 million; the TTM value through Dec 2025 reached -$204.8 million, down 4.57%, while the annual FY2025 figure was -$204.2 million, 4.25% down from the prior year.
  • Net Income reached -$47.5 million in Q4 2025 per PRME's latest filing, up from -$52.8 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of -$16.4 million in Q3 2021 to a low of -$65.6 million in Q4 2023.
  • Average Net Income over 5 years is -$44.4 million, with a median of -$46.6 million recorded in 2024.
  • The largest YoY upside for Net Income was 37.56% in 2022 against a maximum downside of 78.83% in 2022.
  • A 5-year view of Net Income shows it stood at -$62.9 million in 2021, then surged by 37.56% to -$39.3 million in 2022, then tumbled by 67.1% to -$65.6 million in 2023, then surged by 35.6% to -$42.3 million in 2024, then decreased by 12.42% to -$47.5 million in 2025.
  • Per Business Quant, the three most recent readings for PRME's Net Income are -$47.5 million (Q4 2025), -$52.8 million (Q3 2025), and -$52.6 million (Q2 2025).